In two articles in this issue of the Journal, the members of the GRADE Study Research Group1,2 report the findings of the Glycemia Reduction Approaches in Type 2 Diabetes: A Comparative Effectiveness (GRADE) Study, which involved participants who had type 2 diabetes without established cardiovascular complications. These articles have been awaited with great anticipation. Most advances related to cardiovascular benefit in the treatment of type 2 diabetes have been derived from cardiovascular outcome trials involving participants with previous cardiovascular disease, and these advances have been related to secondary prevention. On the basis of those trials, the availability of two new . . .
"type" - Google News
September 22, 2022 at 04:03AM
https://ift.tt/mXMxCO4
After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk | NEJM - nejm.org
"type" - Google News
https://ift.tt/YJOeFXW
https://ift.tt/qUvzht0
Bagikan Berita Ini
Related Posts :
ADA: Abbott's real-world data show FreeStyle Libre lowered A1c in Type 2 diabetes, with or without insulin - FierceBiotech- COVID-19 Testing: What Type To Get And When - KERA News
- Portable Power Station Market by Operation Type, Technology Type, Capacity Type, Application, and Region - Global Forecast to 2025 - ResearchAndMarkets.com - Business Wire
- UTAH STATE GOLF SENIOR FEATURE: Hayden Eckert The Type Of Person Everyone Wants To Be Around - Utah State Aggies
- $13+ Billion Worldwide Mechanical Control Cables Market to 2026 - by Type, Platform, Application, End-user & Geography - GlobeNewswire
0 Response to "After Metformin — Next Steps for Type 2 Diabetes with Low Cardiovascular Risk | NEJM - nejm.org"
Post a Comment